Author:
Lin Chia-Chi,Shih Jin-Yuan,Yu Chong-Jen,Ho Chao-Chi,Liao Wei-Yu,Lee Jih-Hsing,Tsai Tzu-Hsiu,Su Kang-Yi,Hsieh Min-Shu,Chang Yih-Leong,Bai Ya-Ying,Huang Derek De-Rui,Thress Kenneth S,Yang James Chih-Hsin
Subject
Pulmonary and Respiratory Medicine
Reference23 articles.
1. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer;Cross;Cancer Discov,2014
2. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer;Janne;N Engl J Med,2015
3. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component;Yang;J Clin Oncol,2017
4. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study;Goss;Lancet Oncol,2016
5. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer;Mok;N Engl J Med,2017
Cited by
126 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献